cancer drugs
-
Pfizer Expands to Multiple Myeloma With FDA Approval for New Antibody Drug
Oncology is already a big piece of Pfizer’s drug lineup. The portfolio is expanding to multiple myeloma with FDA approval of Elrexfio, a bispecific antibody that targets the cancer protein BCMA.
-
FDA Approves J&J Combo Drug for Prostate Cancers With Certain Genetic Signature
Johnson & Johnson’s Akeega is approved for treating advanced prostate cancer with a BRCA mutation. The drug, which interferes with a way cancer cells repair themselves, will compete against recently approved drugs from Pfizer and partners AstraZeneca and Merck.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
EQRx’s Affordable Drugs Strategy Ends in Acquisition by Revolution, Interested Only in Its Cash
Revolution Medicines is acquiring EQRx in an all-stock deal bringing that company’s more than $1 billion in cash. It marks the end for EQRx, a company that aimed to develop and commercialize lower-cost drugs for cancer and other diseases.
-
Bio Startup Nexo Lands $60M to Climb to New Heights in Cancer Drug R&D
Nexo Therapeutics is developing cancer drugs that expand the scope of amino acids addressable by covalent chemistry. Versant Ventures founded the startup and led its Series A financing.
-
Seagen broadens its scope beyond ADC cancer drugs with deal for preclinical asset
Seagen’s cancer drug research and collaborations have focused on the development of antibody drug conjugates. By licensing rights to a preclinical Lava Therapeutics asset, Seagen gets a shot to develop a different kind of antibody therapy that could compete against approved products from Johnson & Johnson and Takeda Pharmaceutical.
-
FDA advisory committee issues back to back negative votes on two cancer drugs
Spectrum Pharmaceuticals and Oncopeptides each received separate negative advisory committee votes for their respective cancer drugs. In other recent regulatory news, clinical trial holds were placed and lifted and the FDA is seeking public comment on its draft guidance for including children in clinical trials.
-
ASCO recap: Breast cancer breakthrough, Mirati’s moves, Arcellx ascends & more
Breast cancer drugs and cell therapies were prominent in this year’s annual meeting of the American Society of Clinical Oncology. Here’s a recap of some of the news highlights from the biggest cancer conference of the year.
-
BMS bets $4.1B on lung cancer drug that could best products from Pfizer, Roche
Bristol Myers Squibb is splashing out $4.1 billion to acquire Turning Point Therapeutics, a clinical-stage biotech whose lead drug is currently in pivotal testing as a treatment for certain lung cancers. Recently reported preliminary data suggest the small molecule could have advantages over currently available drugs in the same class from rivals Pfizer and Roche.
-
MedCity Influencers, Health Tech
Targeted drug combinations are the next big advance in cancer treatment
Drugs that work for one patient may not work for another, even if both patients have the same diagnosis. This is why each patient should be tested to select the most effective and least toxic drug regimen for that individual before initiating treatment.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
FDA’s tighter scrutiny on drug class leads TG Therapeutics to pull out of cancer
TG Therapeutics is pausing its cancer drug research and withdrawing the approved cancer drug Ukoniq from the market. The move comes as the FDA places greater scrutiny on Ukoniq’s drug class—concerns that will be discussed during an FDA advisory committee meeting scheduled for April 21.
-
Cancer biotech Rondo gets $67M to step on the gas with next-gen bispecific drugs
Rondo Therapeutics is developing bispecific antibody drugs capable of treating solid tumors, which have eluded this type of cancer therapy. Led by co-founders and Teneobio veterans Shelley Force Aldred and Nathan Trinklein, the biotech startup has emerged from stealth backed by a $67 million Series A round of funding.
-
Eli Lilly steers into Foghorn’s gene traffic control drugs with $380M pact in cancer
Eli Lilly is building its cancer drug pipeline via a research alliance with Foghorn Therapeutic, a biotech whose technology discovers drugs addressing targets in a cellular system that regulate the way genes are turned on and off. In paying its new partner $380 million up front, Lilly is also placing yet another bet on targeted protein degradation drugs.
-
FDA turns down BeyondSpring chemo complication drug, asks for another trial
BeyondSpring Pharmaceuticals said the FDA wants another clinical trial to demonstrate patient benefit for its drug, a small molecule developed to treat a dangerous and life-threatening complication of chemotherapy. Shares of the biotech plunged more than 60% after the FDA’s complete response letter was announced.
-
After Phase 3 failure busts blockbuster bid, Deciphera restructures; staff slashed 35%
Deciphera Pharmaceuticals’ corporate restructuring will slash headcount by 35% and stop work on two drug programs. Going forward, the biotech said it will focus on developing drugs that have the potential to be the first or the best in their therapeutic classes.
-
Artificial Intelligence, BioPharma
Sanofi makes $270M bet that a startup’s AI tech can boost its cancer drug R&D
The sum represents Sanofi’s equity investment in Owkin, plus a payment to begin a research partnership covering four types of cancer. Meanwhile, Owkin said the Sanofi investment boosts the startup into unicorn status and marks the start of its Series B funding round.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
